[Correspondence] CONVERTed or not: what are the barriers to implementing the evidence?

We read with interest the results of CONVERT, the multi-institutional phase 3 randomised trial comparing radiotherapy dose schedules for limited-stage small-cell lung cancer by Corinne Faivre-Finn and colleagues.1 Early results from this important clinical trial support the findings from Intergroup 0096 (INT 0096), which established twice-daily radiotherapy as the standard of care for limited-stage small-cell lung cancer in 1999.2

http://ift.tt/2zl2tz3